Display options
Cite
Jakovljevic M, Malmose-Stapelfeldt C, Milovanovic O, et al. Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020. Front Public Health. 2017;5:23doi: 10.3389/fpubh.2017.00023.
Jakovljevic, M., Malmose-Stapelfeldt, C., Milovanovic, O., Rancic, N., & Bokonjic, D. (2017). Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020. Frontiers in public health, 523. https://doi.org/10.3389/fpubh.2017.00023
Jakovljevic, Mihajlo, et al. "Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020." Frontiers in public health vol. 5 (2017): 23. doi: https://doi.org/10.3389/fpubh.2017.00023
Jakovljevic M, Malmose-Stapelfeldt C, Milovanovic O, Rancic N, Bokonjic D. Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020. Front Public Health. 2017 Feb 27;5:23. doi: 10.3389/fpubh.2017.00023. eCollection 2017. PMID: 28289676; PMCID: PMC5327442.
Copy Download .nbib Format: NLM
Share it on

Front Public Health. 2017 Feb 27;5:23. doi: 10.3389/fpubh.2017.00023. eCollection 2017.

Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020.

Frontiers in public health

Mihajlo Jakovljevic, Christina Malmose-Stapelfeldt, Olivera Milovanovic, Nemanja Rancic, Dubravko Bokonjic

Affiliations

  1. Health Economics and Pharmacoeconomics, Faculty of Medical Sciences, University of Kragujevac , Kragujevac , Serbia.
  2. Department of Public Health, The University of Aarhus , Aarhus , Denmark.
  3. Faculty of Medical Sciences, Department of Pharmacy, University of Kragujevac , Kragujevac , Serbia.
  4. Faculty of Medicine of the Military Medical Academy, University of Defence , Belgrade , Serbia.

PMID: 28289676 PMCID: PMC5327442 DOI: 10.3389/fpubh.2017.00023

Abstract

BACKGROUND: Disability either due to illness, aging, or both causes remains an essential contributor shaping European labor markets. Ability of modern day welfare states to compensate an impaired work ability and absenteeism arising from incapacity is very diverse. The aims of this study were to establish and explain intercountry differences among selected European OECD countries and to provide forecasts of future work absenteeism and expenditures on wage replacement benefits.

METHODS: Two major public registries, European health for all database and Organization for Economic Co-operation and Development database (OECD Health Data), were coupled to form a joint database on 12 core indicators. These were related to disability, work absenteeism, and sickness benefits in European OECD countries. Time horizon 1989-2013 was observed. Forecasting analysis was done on mean values of all data for each single variable for all observed countries in a single year. Trends were predicted on a selected time horizon based on the mean value, in our case, 7 years up to 2020. For this purpose, ARIMA prediction model was applied, and its significance was assessed using Ljung-Box Q test.

RESULTS: Our forecasts based on ARIMA modeling of available data indicate that up to 2020, most European countries will experience downfall of absenteeism from work due to illness. The number of citizens receiving social/disability benefits and the number being compensated due to health-related absence from work will decline. As opposed to these trends, cancer morbidity may become the top ranked disability driver as hospital discharge diagnoses. Concerning development is the anticipated bold growth of hospital discharge frequencies due to cancer across the region. This effectively means that part of these savings on social support expenditure shall effectively be spent to combat strong cancer morbidity as the major driver of disability.

CONCLUSION: We have clearly growing work load for the national health systems attributable to the clinical oncology acting as the major disability contributor. This effectively means that large share of these savings on public expenditure shall effectively be spent to combat strong cancer morbidity. On another side, we have all signs of falling societal responsibility toward the citizens suffering from diverse kinds of incapacity or impaired working ability and independence. Citizens suffering from any of these causes are likely to experience progressively less social support and publicly funded care and work support compared to the golden welfare era of previous decades.

Keywords: Europe; OECD; absenteeism; cancer; disability; sickness benefit; work

References

  1. Health Econ. 2016 Sep 29;:null - PubMed
  2. Acta Clin Croat. 2013 Jun;52(2):157-63 - PubMed
  3. Psychooncology. 2008 May;17 (5):421-9 - PubMed
  4. J Occup Med. 1984 Nov;26(11):809-16 - PubMed
  5. Health Policy. 2008 Apr;86(1):109-18 - PubMed
  6. J Med Econ. 2016;19(1):70-6 - PubMed
  7. PLoS One. 2014 Nov 07;9(11):e111931 - PubMed
  8. Int Arch Occup Environ Health. 2003 Apr;76(3):216-24 - PubMed
  9. Health Econ. 2005 Nov;14(11):1087-101 - PubMed
  10. J Econ Perspect. 2006 Summer;20(3):71-96 - PubMed
  11. Expert Rev Pharmacoecon Outcomes Res. 2016 Aug;16(4):537-46 - PubMed
  12. Am J Health Behav. 2008 Jan-Feb;32(1):83-92 - PubMed
  13. Lancet Oncol. 2013 Nov;14(12):1165-74 - PubMed
  14. Lancet. 2016 Oct 8;388(10053):1545-1602 - PubMed
  15. Eur J Health Econ. 2013 Apr;14(2):153-9 - PubMed
  16. Front Pharmacol. 2016 Feb 09;7:18 - PubMed
  17. J Occup Med. 1990 Jan;32(1):9-12 - PubMed
  18. J Health Care Finance. 2000 Spring;26(3):56-72 - PubMed
  19. Vojnosanit Pregl. 2013 Jul;70(7):709-11 - PubMed
  20. J Gerontol. 1992 May;47(3):S98-104 - PubMed
  21. J Med Econ. 2015 Jan;18(1):29-36 - PubMed
  22. Lancet. 2016 Oct 8;388(10053):1459-1544 - PubMed
  23. Arch Phys Med Rehabil. 2007 Jul;88(7):916-21 - PubMed
  24. Lancet. 2016 Oct 8;388(10053):1813-1850 - PubMed
  25. Front Public Health. 2016 Sep 27;4:208 - PubMed
  26. J BUON. 2014 Oct-Dec;19(4):1111-20 - PubMed
  27. Br J Gen Pract. 2011 Mar;61(584):e118-24 - PubMed
  28. Lancet. 2016 Oct 8;388(10053):1659-1724 - PubMed
  29. Lancet. 2012 Nov 24;380(9856):1840-50 - PubMed
  30. BMC Public Health. 2016 Jun 01;16:463 - PubMed
  31. Front Pharmacol. 2016 Feb 12;7:21 - PubMed

Publication Types